Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Positive Patients: A Global Phase 3 Study

Efficacy And Safety ◽

Phase 3 ◽

IDDF2019-ABS-0169 A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

10.1136/gutjnl-2019-iddfabstracts.278 ◽

2019 ◽

Author(s):

Henry Lik Yuen Chan ◽

Pietro Lampertico ◽

Maria Buti ◽

Scott Fung ◽

Sang Hoon Ahn ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Week 96 Efficacy and Safety Results of Tenofovir Alafenamide (TAF) Comparing to Tenofovir Disoproxil Fumarate (TDF) in Chronic Hepatitis B (CHB), HBEAG-Negative, Chronic Hepatitis B Patients: A Global Phase 3 Study

Gastroenterology ◽

10.1016/s0016-5085(17)33661-2 ◽

2017 ◽

Vol 152 (5) ◽

pp. S1086

Author(s):

Maurizia Rossana Brunetto ◽

Young-Suk Lim ◽

Edward Gane ◽

Wai-Kay Seto ◽

Marina Osipenko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

A Phase 3 Study of Tenofovir Alafenamide Compared with Tenofovir Disoproxil Fumarate in Patients with Hbeag-Negative, Chronic Hepatitis B: Week 48 Efficacy and Safety Results

10.1016/s0168-8278(16)01637-8 ◽

2016 ◽

Vol 64 (2) ◽

pp. S135-S136 ◽

Cited By ~ 7

Author(s):

M. Buti ◽

E. Gane ◽

W.K. Seto ◽

H.L.Y. Chan ◽

W.-L. Chuang ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

A phase 3 study comparing tenofovir alafenamide to tenofovir disoproxil fumarate in patients with HBeAg-negative, chronic hepatitis B: efficacy and safety results at week 96

10.1016/s0168-8278(17)30313-6 ◽

2017 ◽

Vol 66 (1) ◽

pp. S25-S26 ◽

Cited By ~ 8

Author(s):

M. Brunetto ◽

Y.S. Lim ◽

E. Gane ◽

W.K. Seto ◽

M. Osipenko ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

FRI-183-A phase 3 study comparing switching from tenofovir disoproxil fumarate to tenofovir alafenamide with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): week 48 efficacy and safety results

10.1016/s0618-8278(19)30928-4 ◽

2019 ◽

Vol 70 (1) ◽

pp. e470-e471

Author(s):

Pietro Lampertico ◽

Maria Buti ◽

Scott Fung ◽

Sang Hoon Ahn ◽

Wan-Long Chuang ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

A phase 3 study comparing switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) with continued TDF treatment in virologically-suppressed patients with chronic hepatitis B (CHB): final week 96 efficacy and safety results

10.1016/s0168-8278(20)30670-x ◽

2020 ◽

Vol 73 ◽

pp. S67-S68

Author(s):

Pietro Lampertico ◽

Maria Buti ◽

Alnoor Ramji ◽

Scott Fung ◽

Sang Hoon Ahn ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

A Phase 3 Study of Tenofovir Alafenamide (TAF) Compared With Tenofovir Disoproxil Fumarate (TDF) in Patients With HBeAg-negative, Chronic Hepatitis B (CHB): Week 48 Efficacy and Safety Results

Clinical Gastroenterology and Hepatology ◽

10.1016/j.cgh.2016.09.108 ◽

2017 ◽

Vol 15 (1) ◽

pp. e44

Author(s):

Henry Lik-Yuen Chan ◽

Scott Fung ◽

Wai Kay Seto ◽

Wan-Long Chuang ◽

Chi-Yi Chen ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

A phase 3 study comparing tenofovir alafenamide (TAF) to tenofovir disoproxil fumarate (TDF) in patients with HBeAg-positive, chronic hepatitis B (CHB): efficacy and safety results at week 96

10.1016/s0168-8278(17)31347-8 ◽

2017 ◽

Vol 66 (1) ◽

pp. S478 ◽

Cited By ~ 16

Author(s):

K. Agarwal ◽

S. Fung ◽

W.K. Seto ◽

Y.S. Lim ◽

E. Gane ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Efficacy And Safety ◽

Phase 3 ◽

Positive Chronic Hepatitis ◽

IDDF2018-ABS-0108 Improved bone and renal safety at 1 year after switching from TENOFOVIR DISOPROXIL FUMARATE (TDF) to TENOFOVIR ALAFENAMIDE (TAF): results from 2 phase 3 studies in HBEAG-positive and HBEAG-negative patients with chronic hepatitis B (CHB)

10.1136/gutjnl-2018-iddfabstracts.209 ◽

2018 ◽

Cited By ~ 1

Author(s):

Henry Lek-Yuen Chan ◽

Calvin Pan ◽

Maurizia Brunetto ◽

Aric Josun Hui ◽

Rajiv Mehta ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Phase 3 ◽

Tenofovir Alafenamide ◽

Renal Safety

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(19)30421-2 ◽

2020 ◽

Vol 5 (5) ◽

pp. 441-453 ◽

Cited By ~ 9

Author(s):

Pietro Lampertico ◽

Maria Buti ◽

Scott Fung ◽

Sang Hoon Ahn ◽

Wan-Long Chuang ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Phase 3 ◽

Double Blind ◽